Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in Myeloma Patients Treated with High-Dose Therapy

Morie A. Gertz, MD
Martha Q. Lacy, MD
Angela Dispenzieri, MD
Philip R. Greipp, MD
Mark R. Litzow, MD
Kimberly J. Henderson
Scott A. Van Wier
Greg J. Ahmann
Rafael Fonseca, MD


Address reprint requests to Morie A. Gertz, MD, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Supported in part by Hematologic Malignancies Fund of Mayo Clinic. Dr. Fonseca is a Clinical Investigator of the Damon Runyon Cancer Research Fund. This work is supported by grants R01 CA83724-01, SPORE P50
CHROMOSOME ABNORMALITIES IN MULTIPLE MYELOMA

CA100707-01 and P01 CA62242 from the National Cancer Institute, and the Fund to Cure Myeloma, and by NCI grant CA21115-25C.

Text word count: 2,032
Abstract word count: 198
No. of tables: 4
No. of figures/parts: 3/6

Running head: Chromosome Abnormalities in Multiple Myeloma
©2005 Mayo Foundation for Medical Education and Research
Abstract

Fluorescent in situ hybridization (FISH) is more sensitive than conventional cytogenetics for recognizing chromosomal changes. Several FISH-detected abnormalities have been associated with inferior prognosis, including deletion of chromosomes 17 and 13 (\(\Delta13\)) and t(4;14)(p16.3;q32). We analyzed the prognostic value of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 2001. All patients had pretransplant cytoplasmic immunoglobulin FISH done on cytospin slides from bone marrow aspirates for t(11;14), t(4;14), and \(\neg17(p13.1)\) (p53). Time to progression and overall survival were significantly shorter for patients with t(4;14) and those with \(\neg17(p13.1)\) but were not affected by t(11;14). Overall survival was significantly shorter for patients with both t(4;14) and \(\Delta13\) abnormalities than for those with \(\Delta13\) alone (26.8 vs 18.8 months). In a multivariable analysis of the effect of \(\Delta13\) and t(4;14), the risk ratio for t(4;14) was greater than for \(\Delta13\) (2.6 vs 1.5). For high-dose therapy patients, \(\neg17(p13)\) and t(4;14) have clinical importance for estimating time to progression and overall survival. The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches.

Key words: chromosome 14 abnormalities; cyclin D1; immunoglobulin heavy chain gene; multiple myeloma; stem cell transplantation
Abbreviations

B2M, β2-microglobulin
ECOG, Eastern Cooperative Oncology Study Group
FISH, fluorescent in situ hybridization
IgH, immunoglobulin heavy chain
LDH, lactate dehydrogenase
MM, multiple myeloma
PCLI, plasma cell labeling index
Introduction

Chromosome translocations involving the immunoglobulin heavy chain (IgH) gene locus define distinct entities of multiple myeloma (MM) with clinical, morphologic, immunophenotypic, and therapeutic implications. The 2 most common IgH translocations are t(4;14)(p16.3;q32) and t(11;14)(q13;q32). These translocations result from illegitimate IgH rearrangements (1). The presence of these rearrangements has been correlated with morphology [plasmablastic with t(4;14)(p16.3;q32) and lymphoplasmacytic or small mature with t(11;14)(q13;q32)] (2) and tumor mass (3). The presence of t(11;14) has also been associated with the presence of CD20 expression on the surface of the cells (4). The t(11;14)(q13;q32) results in upregulation of cyclin D1 and is the most common translocation detected in myeloma (5). It has been suggested that patients with t(11;14) have better survival (6) and response to treatment, particularly high-dose therapy and stem cell support.

In contrast, patients with t(4;14)(p16.3;q32) have an inferior outcome, regardless of the mode of treatment (conventional or high dose) (7). The purpose of our study was to evaluate these translocations with fluorescence in situ hybridization (FISH) using patient samples from a single institution where all the patients were treated with high-dose chemotherapy and stem cell transplantation. The study addresses the clinical implications of these chromosome-14 translocations and the −17(p13.1), p53, deletion on time to progression and overall survival. Multivariable analysis was used to determine whether these abnormalities provide information about patient prognosis not currently available from detection of Δ13 and the biologic
variables β2-microglobulin (B2M) and plasma cell labeling index (PCLI) (8).

Patients and Methods

All patients receiving high-dose chemotherapy with stem cell replacement had a pretransplant bone marrow biopsy performed. All patients gave written informed consent for the collection of additional cells at the time of the bone marrow examination, including separate authorization for genetic studies and separate consent for review of their charts in accord with both U.S. Federal regulations and the Health Insurance Portability and Accountability Act guidelines. The consent form was approved by the Institutional Review Board of Mayo Foundation. In most cases, slides were made with the collected cells, and in some cases, new slides were made from cells frozen in liquid nitrogen. All patients from whom available samples were obtained were included in the analysis. The minimal follow-up for survivors was 36 months. Interphase FISH (9) was combined with immunofluorescence for cytoplasmic immunoglobulin FISH to identify exclusively the plasma cell population (10) and to ensure that all chromosomal abnormalities detected were part of the plasma cell clone. For the detection of these chromosome abnormalities, we used the commercially available probes LSI IgH/FGFR3 [t(4;14)(p16.3;q32)], LSI IgH/CCND1 XT [t(11;14)(q13;q32)], and LSI p53 (17p13.1 deletion) in combination with CEP17 (Vysis, Downers Grove, Illinois) under the same conditions previously published by us (11). Trisomies and abnormalities such as c-MAF (16q23), MAFB (20q11), or cyclin D3 (6p21) were not analyzed as part of this study.
Descriptive statistics were used to characterize the patients. The Fisher exact test was used to test for association between translocations and clinical characteristics for continuous variables. The Wilcoxon rank sum test was used to test for differences between patient groups on the basis of their translocation status. The Fisher exact test was used to test differences among levels of categorical variables between patients with FISH abnormalities. Distributions for survival and progression-free survival were estimated with the Kaplan-Meier method. Log-rank testing was used to assess differences in survival for significance. Multivariable analysis was performed by the Cox method.

**Results**

A total of 238 patients were studied between January 1990 and September 2001. Their characteristics are given in Table 1. The outcomes of patients with the various translocations are summarized in Table 2.

**t(11;14)(q13;q32)**

For the t(11;14)(q13;q32), samples were available to study 197 specimens. This translocation was detected in 34 patients (17%). No differences were found between the patients with and those without the t(11;14)(q13;q32) for age, C-reactive protein level, bone marrow PCLI, serum creatinine, lactate dehydrogenase (LDH), B2M, status at stem cell transplant, and percentage of bone marrow plasma cells. Overall survival and freedom from progression was not different for patients with t(11;14)(q13;q32). Freedom from progression was 20.1 vs 15.3 months, and overall survival was 36.6 vs 34.8 months (Fig. 1A and B). A separate analysis was performed for t(11;14) patients stratified for the presence or
absence of Δ13. No survival advantage was found for t(11;14) patients in Δ13-negative patients.

**t(4;14)(p16.3;q32)**

A successful determination was made in 153 patients. Twenty-six patients (17%) had t(4;14)(p16.3;q32). This chromosome translocation had a profound effect on both time to progression and overall survival. Time to progression for patients with and for those without t(4;14)(p16.3;q32) was 8.2 vs 17.8 months (P=.001), and overall survival was 18.8 vs 43.9 months (P=.001) (Fig. 2A and B). Patients with t(4;14)(p16.3;q32) had a higher C-reactive protein, PCLI, and percentage of bone marrow plasma cells (all P=.04). Age, creatinine, LDH, and B2M, were not significantly different between the 2 groups. There were no differences in the frequency of t(4;14)(q13;q32) among the patients who underwent transplantation at different phases of their disease. No association was found between t(4;14) and heavy chain type (IgA vs not), light chain type (κ vs λ), or the presence of MM bone disease, although only 10% of the patient population had no myeloma bone disease. When the analysis was restricted to the 70 patients who had transplantation upfront in first response, t(4;14)(q13;q32) retained its significance. The median survival rates were 75 months for patients with t(4;14)(p16.3;q32) and 29 months for those without this translocation (P=.01)

**p53**

Of 168 patients for whom analysis was possible, −17p13.1 (p53) was detected in 18 (11%). No differences in p53 status—positive or negative—were detected for age, creatinine, PCLI, LDH, B2M, bone marrow plasma cells, or status at the time of transplantation. The presence of
the \( p53 \) deletions was significant for both the time to progression and overall survival, 8.7 vs 16.1 months and 15.1 vs 38.8 months (\( P < .01 \)), respectively (Fig. 3).

**Interaction Between Abnormalities**

To separate the specific effect of t(4;14)(p16.3;q32) from that of \( \Delta 13 \), an analysis was performed by stratifying \( \Delta 13 \) among patients with t(4;14)(p16.3;q32). In the larger cohort of 212 patients, FISH detected \( \Delta 13 \) in 111 (52%). Of these 111 patients positive for \( \Delta 13 \), 84 had successful studies for t(4;14)(p16.3;q32), of whom 22 (26%) had the abnormality. Survival analysis performed only for patients with \( \Delta 13 \) showed that the presence of t(4;14)(p16.3;q32) had a significant effect on outcome. When both t(4;14)(p16.3;q32) and \( \Delta 13 \) were present, overall survival was 18.8 months, significantly worse than for patients who had \( \Delta 13 \) but not t(4;14)(p16.3;q32) (26.8 months, \( P = .001 \)). The median progression-free survival times were 12.9 vs 8.2 months, respectively (\( P = .001 \)), for \( \Delta 13 \)-positive patients without and those with t(4;14). Conversely, in the t(4;14)-positive cohort, the presence or absence of \( \Delta 13 \) had no effect on survival (19.4 vs 18.8 months).

We constructed a hybrid variable comprising patients who had \( p53 \) deletions or t(4;14)(p16.3;q32) or \( \Delta 13 \) (\( n = 120 \)) with those lacking any of the 3 FISH abnormalities (\( n = 69 \)). Median survival was 26.3 months for those with any of the abnormalities and 51.5 months for those without any abnormality (\( P = .005 \)).

**Assessment of Univariate Effect of Various Characteristics**

Univariate effect on freedom from progression and overall survival was examined for 203 patients in whom studies were performed for
t(4;14)(p16.3;q32); t(11;14)(q13;q32); \( p53 \) deletion; and \( \Delta 13 \) (Table 3). For freedom from progression, the percentage of plasma cells in bone marrow, PCLI, \( \Delta 13 \), \( p53 \) deletions, t(4;14)(p16.3;q32), and the status at stem cell transplant were all significant \( (P<.05) \), and for “overall” survival, B2M, percentage of plasma cells in bone marrow, PCLI, \( \Delta 13 \), \( p53 \) deletions, t(4;14)(p16.3;q32), and status at stem cell transplant were significant. A Cox proportional hazards model was constructed with the characteristics found to be significant in the univariate analysis (Table 4). In this model, the most important characteristic predicting freedom from progression was whether or not the patient received the stem cell transplant at the time of relapse \( (P=.0001) \). In this model, the presence or absence of t(4;14)(p16.3;q32) was significant \( (P=.001) \), as was \( \Delta 13 \) \( (P=.05) \). The risk ratio for patients who received a transplant at the time of relapse was 2.3 (compared with transplant in plateau) and 2.6 for the presence of t(4;14)(p16.3;q32). In the survival model, the most important predictors of survival were PCLI, and patient status at the time of the stem cell transplant, with risk ratios of 1.3 and 2.1, respectively. In this model, t(4;14)(p16.3;q32) was significant to .006, with a risk ratio of 2.2. \( \Delta 13 \) was significant at 0.02, with a risk ratio of 1.7.

When the multivariable analysis was restricted to the 132 patients who had successful analysis for deletion 13, \( p53 \), and t(4;14)(q13;q32) (ie, no missing data), status at transplant was most significant \( (P=.001) \) but t(4;14)(q13;q32) retained its predictive value as well \( (P=.03) \) whereas deletion 13 was marginal \( (P=.08) \). When the impact of \( p53 \) and t(4;14)(q13;q32) was restricted only to patients who had a transplant more than 12 months after diagnosis (late transplant), both features retained
statistical significance in the univariate model, 29.8 vs 16.4 and 29.8 vs 14.2 months for presence or absence of t(4;14)(q13;q32) and p53, respectively; neither retained significance in the multivariable model.

**Discussion**

The t(11;14)(q13;q32) results in upregulation of *cyclin D1* in MM, as in the case of mantle cell lymphoma (3). In an Eastern Cooperative Oncology Study Group (ECOG) protocol with 336 evaluable patients, 16% had t(11;14)(q13;q32) (11) compared with 17% of our high-dose therapy patients, suggesting that the current study had no selection bias. However, in the ECOG study, patients with t(11;14)(q13;q32) appeared to have borderline improvement in survival and response to therapy, whereas our study did not demonstrate any effect on survival or time to progression. Moreau and colleagues (6) have suggested that high-dose therapy for patients with t(11;14)(q13;q32) markedly improves survival. Our results do not corroborate this observation.

In our study, deletions of 17p13.1 at the *p53* locus were clinically important (although not independent) for estimating of overall survival and time to progression. Similar observations have been made for patients who received conventional therapy and those who received high-dose therapy. Chang and colleagues (12) found that patients with *p53* deletions had significantly shorter progression-free (median 7.9 vs 25.7 months, *P* = .0324) and overall survival (median 14.7 vs 48.1 months, *P* = .0008) than patients without a *p53* deletion. In their study, the abnormality retained its independent value in the multivariable model.

Although FISH detection of Δ13 was associated with a poor prognosis in our cohort, the presence of t(4;14)(p16.3;q32) was more
powerful and provided additional information not provided by the presence of $\Delta 13$ alone. The t(4;14)(p16.3;q32) results in the overexpression of fibroblast growth factor receptor 3 and multiple myeloma SET domain (13-15). The negative prognostic effect of t(4;14)(p16.3;q32) appears to be independent of the actual level of fibroblast growth factor receptor 3 expression (7).

In our study, the 2 most important variables were the PCLI of bone marrow (a measure of the fraction of plasma cells in the S phase) and the status of the patient at stem cell transplant (ie, whether the transplant was performed at the time of relapse). Because of the low prevalence of these abnormalities (15%), a much larger study is needed to elucidate the actual prognostic implications of these chromosome abnormalities.

Our patients with t(4;14)(p16.3;q32) had a median time to progression of only 8.2 months after stem cell therapy and an overall survival of 18.8 months. This suggests that high-dose therapy, as currently practiced, has minimal benefit for these patients. Whether the addition of nonmyeloablative strategies will overcome these therapeutic limitations is not known; thus, they cannot be deemed best therapy for this high-risk group of patients. Also, the dismal outcome for t(4;14)(p16.3;q32) after a stem cell transplant raises the question of the role of allogeneic transplantation in suitable younger candidates. Currently, preclinical and early clinical investigations are being developed for the treatment of patients with IgH chain translocations. Until these therapies are available, patients should be considered candidates for novel therapeutic approaches.

At Mayo Clinic, a FISH panel is routinely performed for all patients with newly diagnosed MM and includes FISH assessment for
4p16.3 (FGFR3), 11q13 (CCND1-XT), 13q14 (Rb1), 13q34 (LAMP1),
14q32 (IGH5,’IGH3′), 14q32 (IGH-XT), 16q23 (c-MAF), 17p12 (p53), and
17cen (D17Z1). The presence of p53 deletion, t(4;14), or Δ13 halves
survival from 51.5 to 26.3 months.
References


CHROMOSOME ABNORMALITIES IN MULTIPLE MYELOMA


### Table 1. Characteristics of the 238 Study Patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Range</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, no.</td>
<td>142</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>30-71</td>
<td>56</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.7-3.5</td>
<td>1.1</td>
</tr>
<tr>
<td>$\beta_2$-Microglobulin, mg/dL</td>
<td>0.9-11.2</td>
<td>2.53</td>
</tr>
<tr>
<td>Bone marrow labeling index, %</td>
<td>0-8.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Bone marrow plasma cells, %</td>
<td>0-95</td>
<td>20</td>
</tr>
<tr>
<td>Serum M protein, g/dL</td>
<td>0-10.4</td>
<td>1.6</td>
</tr>
<tr>
<td>Urine protein, g/dL</td>
<td>0.007-10.4</td>
<td>0.09</td>
</tr>
<tr>
<td>Time from diagnosis to bone marrow transplant, mo</td>
<td>3.7-87.5</td>
<td>6.7-31.7 (25%-75%)</td>
</tr>
<tr>
<td>Status at transplant, no. of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plateau</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Primary induction failure</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Relapse off therapy</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Relapse on therapy (resistant relapse)</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Summary of FISH Findings for 11;14, 4;14, and p53

<table>
<thead>
<tr>
<th></th>
<th>Successful determination, no. of patients</th>
<th>Patients with translocation or deletion, no. (%)</th>
<th>Overall survival with/without abnormality, median no. of mo</th>
<th>Progression-free survival with/without abnormality, median no. of mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(11;14)(q13;q32)</td>
<td>197</td>
<td>34 (17)</td>
<td>36.6/34.8</td>
<td>20.1/15.3</td>
</tr>
<tr>
<td>−17p13.1 (p53)</td>
<td>168</td>
<td>18 (11)</td>
<td>15.1/38.8*</td>
<td>8.7/16.1*</td>
</tr>
<tr>
<td>t(4;14)(p16.3;q32)</td>
<td>153</td>
<td>26 (17)</td>
<td>18.8/43.9†</td>
<td>8.2/17.8†</td>
</tr>
<tr>
<td>t(4;14) +(p16;q32)Δ13</td>
<td>84</td>
<td>22 (26)</td>
<td>18.8/26.8*</td>
<td>8.2/12.9†</td>
</tr>
</tbody>
</table>

FISH, fluorescent in situ hybridization.

*P≤.01.
†P<.001.
Table 3. Univariate Predictors of Outcome for 203 Patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall survival log-rank $P$ value</th>
<th>Freedom from progression log-rank $P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>.21</td>
<td>.56</td>
</tr>
<tr>
<td>Serum M spike</td>
<td>.9</td>
<td>.82</td>
</tr>
<tr>
<td>Urine total protein</td>
<td>.1</td>
<td>.25</td>
</tr>
<tr>
<td>$\beta_2$-Microglobulin</td>
<td>.016</td>
<td>.14</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>.48</td>
<td>.6</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>.07</td>
<td>.64</td>
</tr>
<tr>
<td>Bone disease</td>
<td>.11</td>
<td>.49</td>
</tr>
<tr>
<td>% Plasma cells in bone marrow</td>
<td>.0002</td>
<td>.0001</td>
</tr>
<tr>
<td>Plasma cell labeling index</td>
<td>.0001</td>
<td>.0001</td>
</tr>
<tr>
<td>Creatinine</td>
<td>.42</td>
<td>.88</td>
</tr>
<tr>
<td>Age</td>
<td>.77</td>
<td>.77</td>
</tr>
<tr>
<td>$\Delta 13q$</td>
<td>.004</td>
<td>.017</td>
</tr>
<tr>
<td>$-17p13.1$ $(p53)$</td>
<td>.04</td>
<td>.003</td>
</tr>
<tr>
<td>$t(11;14)(q13;q32)$</td>
<td>.7</td>
<td>.35</td>
</tr>
<tr>
<td>$t(4;14)(p16.3;q32)$</td>
<td>.0001</td>
<td>.0001</td>
</tr>
<tr>
<td>Status at stem cell transplant</td>
<td>.0001</td>
<td>.0001</td>
</tr>
</tbody>
</table>
Table 4. Cox (Multivariable) Analysis of Characteristics Affecting Time to Progression and Overall Survival

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Time to progression</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P value</td>
<td>Risk ratio</td>
</tr>
<tr>
<td>Status at stem cell transplant</td>
<td>.0001</td>
<td>2.3</td>
</tr>
<tr>
<td>t(4;14)(p16.3;q32)</td>
<td>.001</td>
<td>2.6</td>
</tr>
<tr>
<td>−17p13.1 (p53)</td>
<td>.08</td>
<td>1.9</td>
</tr>
<tr>
<td>Δ13</td>
<td>.05</td>
<td>1.5</td>
</tr>
<tr>
<td>Plasma cell labeling index</td>
<td>.01</td>
<td>1.2</td>
</tr>
<tr>
<td>β2-Microglobulin</td>
<td>.53</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Legends

Fig. 1. Patients with and without t(11;14)(q13;q32) translocation. A, Time to progression; B, overall survival. BMT, bone marrow transplant.

Fig. 2. Patients with and without t(4;14)(p16.3;q32) translocation. A, Freedom from progression; B, overall survival. BMT, bone marrow transplant.

Fig. 3. −17p13.1, p53. A, Freedom from progression; B, overall survival. BMT, bone marrow transplant.
Fig. 1A

- **t(11;14)(q13;q32) absent (n=163)**
- **t(11;14)(q13;q32) present (n=34)**

Median 20.1 vs 15.3
GERTZ et al
-23- tjh (OEM)
CHROMOSOME ABNORMALITIES IN MULTIPLE MYELOMA

Fig. 1B

![Survival curve showing the comparison between t(11;14)(q13;q32) absent and present. The median survival is 34.8 months for absent and 36.6 months for present.](image-url)
Fig. 2A

- t(4;14)(p16.3;q32) absent (n=127)
- t(4;14)(p16.3;q32) present (n=26)

Median 17.8 vs 8.2
Fig. 2B

**Graph**

- **t(4;14)(p16.3;q32) absent (n=127)**
- **t(4;14)(p16.3;q32) present (n=26)**

Median 43.9 vs 18.8

**Fraction surviving**

**Survival from BMT, mo**
Fig. 3A

- p53 wild type (n=150)
- p53 deleted (n=18)

Median 16.1 vs 8.7
Fig. 3B

Fraction surviving

Survival from BMT, mo

- p53 wild type (n=150)
- p53 deleted (n=18)

Median 38.8 vs 15.1
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Philip R Greipp, Mark R Litzow, Kimberly J Henderson, Scott A Van Wier, Greg J Ahmann and Rafael Fonseca

Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.